Evidence map›Paper›PMID 42660557›Full record

ArticleBMJ open2026

Feasibility, validation and application of digital tools for remote monitoring in neuromuscular diseases: the DT4RD protocol.

Jean-Yves Hogrel, Pauline Santmarty, Valérie Decostre, Thomas Marques, Erwan Gasnier, Marion Masingue, Giorgia Querin, Micha Paalman, Sjaak Kok, Jolinda Horstik and 10 more

Registry-linked trialAbstract readValidation Study
In one paragraph

Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05798325 (Feasibility, Validation and Application of Digital Tools for the Follow-up of Neuromuscular Patient), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05798325 nacompletednot on this map

Feasibility, Validation and Application of Digital Tools for the Follow-up of Neuromuscular Patient

TypeinterventionalSponsorInstitut de Myologie, FranceRan2023 to 2025Enrolled40ConditionsNeuromuscular DiseasesArms2MWT, MFM32, MyoGrip, QOL-gNMD, Spirometry
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Jean-Yves HogrelInstitute of Myology, Paris, Île-de-France, France jy.hogrel@institut-myologie.org.ORCID http://orcid.org/0000-0003-0045-7505
Pauline SantmartyInstitute of Myology, Paris, Île-de-France, France.
Valérie DecostreInstitute of Myology, Paris, Île-de-France, France.
Thomas MarquesInstitute of Myology, Paris, Île-de-France, France.
Erwan GasnierInstitute of Myology, Paris, Île-de-France, France.
Marion MasingueInstitute of Myology, Paris, Île-de-France, France.
Giorgia QuerinInstitute of Myology, Paris, Île-de-France, France.
Micha PaalmanYumen Bionics, Amsterdam, Netherlands.
Sjaak KokYumen Bionics, Amsterdam, Netherlands.
Jolinda HorstikYumen Bionics, Amsterdam, Netherlands.
Mohammed A SangadjiYumen Bionics, Amsterdam, Netherlands.
Paulien KlapYumen Bionics, Amsterdam, Netherlands.
Elisa Ferrer-MallolAparito Ltd, Wrexham, UK.
Caroline Le BarbierAparito Ltd, Wrexham, UK.
Laura Smith Van CarrollMetabolic Support, Manchester, UK.
Kirsty HoyleMetabolic Support, Manchester, UK.
Anna G MayhewThe John Walton Muscular Dystrophy Research Centre, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle, UK.
Robert Muni-LofraThe John Walton Muscular Dystrophy Research Centre, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle, UK.
Elin Haf DaviesAparito Ltd, Wrexham, UK.
Volker StraubThe John Walton Muscular Dystrophy Research Centre, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRare diseases (RDs) affect millions of people worldwide and present major challenges for research due to small patient populations, limited longitudinal data and the difficulty of capturing real-world disease manifestations. Digital technologies provide new opportunities to collect multimodal data directly from patients and their environments. In particular, video recordings, wearable-based physical activity monitoring and digital questionnaires can generate detailed, longitudinal information on symptoms, functional abilities and daily-life impact. The digital tools for rare disorders (DT4RD) protocol aims to develop and evaluate a digital framework that integrates these technologies to support data collection and analysis in RD research. METHODS AND ANALYSIS: DT4RD will implement a technology-driven platform designed to collect and analyse multimodal patient-generated data. The protocol includes three main components: (1) structured video capture to document clinical signs and functional performance, enabling remote assessment and computational analysis; (2) continuous physical activity monitoring using wearable sensors to quantify mobility and daily activity patterns and (3) digital questionnaires to capture patient-reported outcomes and contextual information. These data streams will be integrated within a dedicated digital infrastructure supporting secure data collection, storage and analysis. This pilot study will be conducted with participants affected by rare neuromuscular diseases to evaluate the feasibility, usability and analytical potential of the platform as well as its ability to generate clinically relevant insights from multimodal digital data anchored to regular hospital visits. ETHICS AND DISSEMINATION: The study was approved in France by the TRIAL REGISTRATION NUMBER: NCT05798325.

Indexed as

Neuromuscular DiseasesRare DiseasesDigital HealthFeasibility StudiesHumansPilot ProjectsRemote Patient MonitoringSurveys and QuestionnairesVideo RecordingWearable Electronic DevicesClinical TrialDigital TechnologyeHealthNeuromuscular diseasePatient Reported Outcome MeasuresWearable Devices

Identifiers

PMID42660557
PMCPMC13536152

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.